Nuon Therapeutics, Inc.

Nuon Therapeutics Announces Data Demonstrating Uric Acid Lowering Activity of Tranilast To Be Presented at EULAR 2010

SAN MATEO, Calif., June 3, 2010 – Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that two scientific abstracts on the activity of tranilast against key components of gout – high serum uric acid levels and monosodium urate crystal-induced inflammation – have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.

EULAR 2010 Abstracts on Tranilast:

EULAR Abstract #SAT 0369
Tranilast, a novel, potential treatment for the chronic management of hyperuricemia in patients with gout, reduces serum uric acid (SUA) in healthy subjects.
Poster: Saturday, June 19, 2010, 10:15 AM: Fiera Roma- Poster Area in Hall 5

EULAR Abstract #AB 0054
Tranilast suppresses inflammation induced by monosodium urate (MSU) crystals in vivo. Abstract only.

Abstracts are available on the League's website: www.eular.org.
(https://b-com.mci-group.com/AbstractList/EULAR10.aspx)

Nuon Therapeutics' lead product, NU1618, is a proprietary combination of tranilast and allupurinol currently in phase 2 development for the treatment of hyperuricemia in patients with gout. Topline data from a completed proof-of-principle, phase 2a study of NU1618 will be released later this month.

About Nuon Therapeutics, Inc.

Nuon Therapeutics, Inc. is a privately held, clinical stage, biopharmaceutical company that is developing small molecule drugs to address critical, unmet medical needs in autoimmune and rheumatic diseases. The Company was founded in 2006 and has raised a total of $38 million from investors including Domain Associates, L.L.C., Frazier Healthcare Ventures, and GBS Venture Partners. Nuon Therapeutics, Inc. has its headquarters in San Mateo, CA. For additional information, please visit: www.nuontherapeutics.com

Contact: